Growth disorders: cross-border specialty drug access for international patients

Quick orientation

Growth hormone deficiency affects an estimated 1 in 3,500 to 10,000 children. Other growth disorders including idiopathic short stature, Turner syndrome, and chronic kidney disease-related growth failure expand the eligible population.

Typical age of onset. Most commonly diagnosed in childhood; some forms persist into adult growth hormone deficiency.

Severity tiers. Severity is graded by stimulated growth hormone response and growth velocity. Untreated severe forms result in substantial short stature.

Why specialty drugs for Growth disorders are hard to access internationally

Long-acting weekly growth hormone formulations (e.g., somatrogon, somapacitan) are newer and not yet registered in all markets. Standard daily growth hormone is broadly available, but the convenience advantage of weekly products is a major access driver.

Treatments approved by the FDA

• Ngenla (somatrogon-ghla) — FDA approval: 2023. Mechanism: Long-acting recombinant human growth hormone. Route: Subcutaneous injection once weekly. US WAC ballpark: Approximately USD 60,000 to 80,000 per year, weight-based. Country pricing: India · Egypt.

Cross-border pathways used for Growth disorders

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm diagnosis with stimulation testing where applicable.
• Document growth velocity, bone age, and IGF-1 levels.
• Pediatric endocrinologist co-management is required.
• Counsel families on injection technique and storage.
• Monitor for adverse events including injection-site reactions and IGF-1 elevation.

Common questions

How does once-weekly compare to daily growth hormone?

Efficacy is comparable; once-weekly dosing simplifies administration.

Is Ngenla available in my country?

Registration varies. We confirm by destination.

Can adults use these products?

Long-acting growth hormone labels and adult indications vary; consult your endocrinologist.

How is dose adjusted?

Weight-based dosing; updates with each refill as the child grows.

What documents are required?

Pediatric endocrinologist's prescription, growth chart, bone age, and stimulation test results.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Growth disorders, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Growth disorders

Reserved for you.